Quantcast

Synova Healthcare Continues Retail Expansion of Fem-V(TM)

June 13, 2007

MEDIA, Pa., June 13 /PRNewswire-FirstCall/ — Synova Healthcare, Inc., a subsidiary of Synova Healthcare Group, Inc. (BULLETIN BOARD: SNVH) , has recently expanded the distribution of Fem-V(TM) through Longs Drugs. Longs Drugs is one of the most recognized retail drug store chains on the West Coast. Longs, a California based company operates more than 500 stores in California, Hawaii, Washington, Nevada, Colorado and Oregon.

Millions of women buy over-the-counter (OTC) vaginal infection treatments, often without knowing the root cause of their vaginal infections. Although some infections can be treated with OTC products successfully, others cannot, and require a prescription from their health care provider. Fem-V, with its advanced polymer technology, can assist a woman in assessing whether she should seek professional care for her vaginal infection symptoms.

Fem-V is a non-invasive, at-home test with a diagnostic strip embedded in a pantiliner. It is highly accurate with 91% sensitivity and provides results that are easy to interpret. Fem-V provides women with a private and comfortable way to assess their vaginal infection symptoms.

Stephen E. King, Chairman and CEO of Synova Healthcare Group, Inc. said, “We are extremely pleased to announce Fem-V’s distribution through Longs. Longs represents another very important point of retail distribution for Fem-V and increases access to this product for our customers. We believe Fem-V can play an important role for the millions of women who suffer from vaginal infections annually.”

The Company also believes that many of the consumers, who will use Fem-V, represent the same target audience for The Today(R) Sponge. Synova Healthcare acquired the exclusive worldwide rights to the Today Sponge earlier this year, and will soon re-launch this former #1 OTC female contraceptive to consumers nationwide. The Company intends to aggressively co-promote and cross merchandise these two strategically aligned healthcare products in the months ahead. Interested consumers can learn more about Fem-V by visiting http://www.fem-v.com/ .

About Synova Healthcare Group, Inc.:

Synova Healthcare Group, Inc. is committed to delivering innovative products that provide meaningful improvements in women’s healthcare. Through its subsidiaries, it is focused on the development, distribution, marketing and sale of women’s healthcare products related to contraception, vaginal health, menopause management, fertility planning, obstetrics and personal care. Its goal is to provide healthcare solutions that address every stage of a woman’s reproductive life. Synova currently markets and sells products under the brand names Today(R), Fem-V(TM), MenoCheck(R) and MenocheckPro(R). The Today(R) Sponge is a non-hormonal contraceptive that combines barrier, spermicidal and absorptive methods to prevent conception. Fem-V(TM) is a non-invasive diagnostic test designed to assist women in detecting and diagnosing the presence of elevated vaginal acidity, often indicating a vaginal infection. MenoCheck(R) and MenocheckPro(R) are in-home and in-office non-invasive diagnostic tests used to detect and diagnose the onset of menopause. For more information, please visit the Company’s website at http://www.synovahealthcare.com/ .

This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as “anticipates”, “believes”, “estimates”, “expects”, “plans”, “intends”, “potential” and similar expressions. These statements reflect the Company’s current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance or achievements to differ materially from those expressed in or implied by such statements. Such risk factors are discussed in the Company’s Registration Statement on Form SB- 2 (File No. 333-123498), as amended, as declared effective by the Securities and Exchange Commission on May 22, 2006, as well as in other periodic reports and filings with the Commission. There can be no assurance that such factors will not affect the accuracy of such forward-looking statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information set forth in this Press Release including such forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy; nor will there be any sale of securities of Synova Healthcare Group, Inc. in any state where such offer, solicitation or sale would be unlawful before registration or qualification under the securities laws of those states.

Synova Healthcare, Inc.

CONTACT: Corporate Relations: Mr. Robert Edwards, Chief FinancialOfficer of Synova Healthcare Group, Inc., +1-610-565-7080, redwards@snvh.com;Investor Relations: Mr. Adam Holdsworth of Investor Relations Group, +1-212-825-3210

Web site: http://www.synovahealthcare.com/http://www.fem-v.com/




comments powered by Disqus